Find generic entry opportunities
Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Drug patents …
… from Kazakhstan to Kalamazoo
Anticipate generic drug launch
Manage your formulary budget
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Method of progesterone delivery and affect thereof|
|Abstract:||The present invention teaches that relatively low levels of serum progesterone, 1 to 6 ng/ml, may be used to prevent endometrial cancer. The vaginal delivery of progesterone using a cross-linked polycarboxylic polymer produces this low serum progesterone level while also providing the full secretory transformation of the endometrium, indicating the efficacy of the progesterone. Such low levels of serum progesterone will decrease the risk of breast cancer experienced by women undergoing hormone replacement therapy ("HRT") and minimize the potential of other undesirable progesterone associated side effects.|
|Inventor(s):||Bologna; William J. (New York, NY), Levine; Howard L. (Oceanside, NY)|
|Assignee:||Columbia Laboratories, Inc. (Coconut Grove, FL)|
Patent Claim Types:|
see list of patent claims
|Use; Delivery; Device;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Austria||174796||<disabled in preview>|
|Australia||689133||<disabled in preview>|
|Australia||7726194||<disabled in preview>|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.